Is ALNY or ZTS cheaper?

On trailing earnings, ZTS is cheaper: ALNY trades at a 66.81 P/E and ZTS at 12.28.

Which has grown faster, ALNY or ZTS?

Over the past five years, ALNY grew revenue faster — ALNY at a 49.67% CAGR versus ZTS at 6.28%.

Does ALNY or ZTS pay a bigger dividend?

ZTS pays a dividend (2.78% yield) while ALNY does not currently pay one.

Is ALNY or ZTS more profitable?

ZTS runs the higher net margin — ALNY at 13.46% versus ZTS at 27.79%.

Which has been the better investment, ALNY or ZTS?

Over the past 10-year, ALNY delivered the higher annualized total return — ALNY at 16.14% versus ZTS at 4.86%. Past performance doesn't predict future results.

Alnylam Pharmaceuticals, Inc. (ALNY) vs Zoetis Inc. (ZTS)

ZTS leads on 10 of 14 compared metrics.

A side-by-side comparison of Alnylam Pharmaceuticals, Inc. and Zoetis Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 15, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

ALNY

Alnylam Pharmaceuticals, Inc.

$37.46B

$280.59HealthcareDelayed quote: Jul 15, 2026, 11:45 AM EDT

ZTS

Zoetis Inc.

$31.32B

$74.71HealthcareDelayed quote: Jul 15, 2026, 11:44 AM EDT

Total return — ALNY vs ZTS

growth of $100 · dividends reinvested · last 13y

ALNY +1060.3%ZTS +166.4%ALNY compounded faster

ALNY ZTS

ALNY vs ZTS: by the numbers

•ALNY is the larger company ($37.46B vs $31.32B market cap).
•ZTS trades at the lower earnings multiple (12.28 vs 66.81 P/E).
•ZTS converts more revenue to profit (27.79% vs 13.46% net margin).
•ALNY grew revenue faster over the past five years (49.67% vs 6.28% CAGR).
•ZTS pays a dividend (2.78% yield) while ALNY does not currently pay one.

Which is better, ALNY or ZTS?

Metric tally: ALNY 4 · ZTS 10

It depends on what you're optimizing for:

ValueZTS(lower P/E)

GrowthALNY(faster 5Y revenue CAGR)

QualityZTS(higher ROIC)

Metrics side by side

Valuation

Metric	ALNY	ZTS
P/E ratio	66.81	12.28●
Forward P/E	37.91	10.76●
P/S ratio	9.07	3.29●
P/B ratio	36.15	9.68●
PEG ratio	—	2.04
EV / EBITDA	47.64	9.50●
FCF yield	1.65%	6.83%●

Profitability

Metric	ALNY	ZTS
Gross margin	80.89%●	70.75%
Operating margin	17.54%	37.57%●
Net margin	13.46%	27.79%●
ROE	53.68%	81.75%●
ROIC	13.74%	21.54%●

Dividends

Metric	ALNY	ZTS
Dividend yield	—	2.78%
Payout ratio	—	34.16%

Growth (annualized)

Metric	ALNY	ZTS
Revenue CAGR (5Y)	49.67%●	6.28%
EPS CAGR (5Y)	—	11.88%
FCF CAGR (5Y)	14.35%●	4.90%
Total return CAGR (5Y)	10.55%●	-17.29%

Frequently asked

Which is better, ALNY or ZTS?: It depends on your goal. value: ZTS (lower P/E); growth: ALNY (faster 5Y revenue CAGR); quality: ZTS (higher ROIC). Across all compared metrics, ZTS leads 10 to 4.
Is ALNY or ZTS cheaper?: On trailing earnings, ZTS is cheaper: ALNY trades at a 66.81 P/E and ZTS at 12.28.
Which has grown faster, ALNY or ZTS?: Over the past five years, ALNY grew revenue faster — ALNY at a 49.67% CAGR versus ZTS at 6.28%.
Does ALNY or ZTS pay a bigger dividend?: ZTS pays a dividend (2.78% yield) while ALNY does not currently pay one.
Is ALNY or ZTS more profitable?: ZTS runs the higher net margin — ALNY at 13.46% versus ZTS at 27.79%.
Which has been the better investment, ALNY or ZTS?: Over the past 10-year, ALNY delivered the higher annualized total return — ALNY at 16.14% versus ZTS at 4.86%. Past performance doesn't predict future results.

Go deeper

Full ALNY analysis Full ZTS analysis Interactive comparison tool

Dig into the metrics

Alnylam Pharmaceuticals P/E ratio Zoetis P/E ratio Alnylam Pharmaceuticals dividend yield Zoetis dividend yield Alnylam Pharmaceuticals ROE Zoetis ROE Alnylam Pharmaceuticals operating margin Zoetis operating margin Alnylam Pharmaceuticals revenue growth Zoetis revenue growth Alnylam Pharmaceuticals free cash flow Zoetis free cash flow

Alnylam Pharmaceuticals & Zoetis appear in these rankings

Highest Dividend Yield Stocks Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 15, 2026.